The ALIGN-AR trial contributes to the literature by demonstrating high technical success, a reassuring safety profile, and favorable clinical outcomes in high-risk patients with aortic regurgitation ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, ...

"Refocusing and reframing the definition and discussion of coronary artery disease (CAD) from late-stage ischemia and acute coronary events to early detection of coronary artery atheroma and ...

One of the most significant modifications that middle-aged patients can take to prevent cardiovascular disease is lowering arterial hypertension, according to research presented during a Featured ...

Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less likely ...

Implantation of an intra-aortic balloon pump (IABP) did not improve 60-day survival or bridge to heart replacement (HRT) therapies in patients with heart failure-cardiogenic shock (HF-CS) compared to ...

The HERZCHECK trial demonstrates the feasibility and diagnostic value of a mobile, CMR-based screening strategy for detecting asymptomatic stage B HF in rural, high-risk populations. Participants in ...

A 21-year-old male collegiate football player presents for an annual physical examination with blood pressure (BP) elevated to 147/82 mm Hg. He is counseled on lifestyle modifications, including the ...

Clopidogrel monotherapy was found to be more effective than aspirin monotherapy in lowering risk of major adverse cardiac and cerebrovascular events among patients at high risk of recurrent ischemic ...

Intravenous (IV) iron supplementation with ferric carboxymaltose was found to be well tolerated and improve quality of life in patients with heart failure with reduced ejection fraction (HFrEF) and ...

The ZENITH trial demonstrated that among high-risk adults with PAH on maximum tolerated dose of background therapy, treatment with sotatercept resulted in a lower risk of all-cause death, lung ...

Coronary atherosclerotic phenotypes, including total plaque volume (TPV), noncalcified plaque (NCP), calcified plaque (CP) and percentage atheroma volume (PAV), assessed by artificial ...